Nevertheless, taking into consideration that the knockdown of ELOVL6 also has a significant effect on normal colon cells, whereas the silencing of ELOVL4 specifically decreases the proliferation of CRC cells without affecting normal colon cells, targeting ELOVL4 appears to be more promising as a potential CRC therapy. This evidence concerns the gene ELOVL4 and colorectal carcinoma.